News stories about Exelixis (NASDAQ:EXEL) have trended somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Exelixis earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.9150198304637 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

A number of research analysts have recently issued reports on EXEL shares. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research note on Thursday, July 27th. Stifel Nicolaus reaffirmed a “hold” rating and set a $26.00 price objective on shares of Exelixis in a research note on Thursday, August 3rd. Deutsche Bank AG cut Exelixis from a “buy” rating to a “hold” rating and raised their price objective for the company from $26.00 to $29.00 in a research note on Thursday, August 3rd. Piper Jaffray Companies reaffirmed a “buy” rating and set a $29.00 price objective on shares of Exelixis in a research note on Thursday, August 3rd. Finally, TheStreet raised Exelixis from a “c” rating to a “b-” rating in a research note on Monday, August 7th. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $31.38.

Exelixis (NASDAQ EXEL) traded up $0.08 during midday trading on Wednesday, hitting $26.13. The company had a trading volume of 1,526,914 shares, compared to its average volume of 4,181,429. The company has a market capitalization of $7,730.00, a PE ratio of 50.29, a PEG ratio of 1.15 and a beta of 1.89. Exelixis has a 12 month low of $14.22 and a 12 month high of $32.50.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.18. The company had revenue of $152.50 million for the quarter, compared to analysts’ expectations of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. Exelixis’s quarterly revenue was up 145.2% on a year-over-year basis. During the same period last year, the firm earned ($0.04) earnings per share. research analysts predict that Exelixis will post 0.49 EPS for the current fiscal year.

In other Exelixis news, Director Stelios Papadopoulos sold 10,000 shares of the firm’s stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $25.40, for a total value of $254,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gisela Schwab sold 100,000 shares of the firm’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $23.79, for a total transaction of $2,379,000.00. The disclosure for this sale can be found here. Insiders sold 970,152 shares of company stock valued at $25,923,457 over the last 90 days. 5.10% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Exelixis (EXEL) Stock Price” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Stock Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related stocks with our FREE daily email newsletter.